This Amendment No. 1 to Schedule 13G (this “Amendment”)
amends and supplements the Schedule 13G filed by Freebird Partners
LP with the Securities and Exchange Commission (the
“Commission”) on December 2, 2022 (the “Schedule
13G”), relating to Common Stock of the Issuer to reflect the
beneficial ownership of the Warrant Shares by the Reporting Persons
(as defined below), because the Warrant is exercisable within 60
days of April 3, 2023.
Eterna Therapeutics Inc.
Address of Issuer’s Principal Executive
10355 Science Center Drive, Suite 150
San Diego, CA 92121
Name of Person Filing
This statement is filed by the following entities and individuals
(collectively, referred to as the “Reporting
Freebird Partners LP, a Texas limited partnership;
Freebird Investments LLC, a Texas limited liability company;
Curtis W. Huff, an individual and a citizen of the United States of
Freebird Investments LLC is the general partner of Freebird
Partners LP, and as a result, may be deemed to share voting and
dispositive power with respect to the securities held by Freebird
Curtis Huff is the sole member of Freebird Investments LLC, which
is the general partner of Freebird Partners LP, and as a result,
may be deemed to share voting and dispositive power with respect to
the securities held by Freebird Partners LP.
Freebird Partners LP, Freebird Investments LLC, and Mr. Huff
have entered into a Joint Filing Agreement, a copy of which was
filed with the Schedule 13G on December 2, 2022 as Exhibit 99.1,
which is hereby incorporated by reference, pursuant to which they
have agreed to file this Amendment jointly in accordance with the
provisions of Rule 13d-1(k)
of the Act.
Address of Principal Business Office or, if none,
The address of the principal business office for each of the
Reporting Persons is:
2800 Post Oak Blvd, Suite 2000
Houston, TX 77056
See Row 4 of cover page for each Reporting Person.
Title of Class of Securities
Common stock, par value $0.005 per share.